Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.92
- Piotroski Score 2.00
- Grade Buy
- Symbol (OCUP)
- Company Ocuphire Pharma, Inc.
- Price $1.17
- Changes Percentage (-12.03%)
- Change -$0.16
- Day Low $1.07
- Day High $1.36
- Year High $3.40
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.47
- Trailing P/E Ratio -3.6
- Forward P/E Ratio -3.6
- P/E Growth -3.6
- Net Income $-9,986,000
Income Statement
Quarterly
Annual
Latest News of OCUP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ocuphire and Opus Genetics merge to develop IRD gene therapy
Ocuphire Pharma acquires Opus Genetics to form Opus Genetics, focusing on gene therapy for inherited retinal diseases. The merger involves stock issuance and preferred shares conversion, aiming to acc...
By Yahoo! Finance | 3 weeks ago -
Here's Why We're Not At All Concerned With Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Investors are attracted to unprofitable companies due to potential high returns. Ocuphire Pharma's cash burn analysis reveals a long cash runway despite falling revenue, indicating its ability to mana...
By Yahoo! Finance | 3 months ago
